The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast

Abstract

In order to explore the value of p63, smooth muscle actin (α-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining. By using immunohistochemistry, the expression of p63, α-SMA and CK5/6 was detected. The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and α-SMA. In 19 cases of ductal carcinoma in situ (DCIS) and 7 cases of intraductal papillary carcinoma, α-SMA positive cells formed a layer of continuous embroider-shaped structure and the p63 positive cells formed a layer of evenly separated embroider-shaped structure around the ducts. There was no cross-reaction between p63 and interstitial myofibroblasts and vascular smooth muscle cells. In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100 %. In 5 cases of atypical ductal hyperplasia, there were few positive cells in the ducts. In 19 cases of CDIS, no tumor cells expressed CK5/6. In 19 cases of invasive ductal carcinoma, almost no CK5/6 was detectable. It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells. CK5/6 is of value in differentiating ductal proliferation of varying degrees, especially in the differentiation between cancerous and non-cancerous changes. Simultaneous detection of p63, CK5/6 and α-SMA can help increase the diagnostic accuracy of breast diseases.

Keywords

immuohistochemistry / breast / pathological diagnosis / p63 / CK5/6

References

[1] BarbareschiM., PecciariniL., CangiM. G., et al.. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol, 2001, 25(8): 1054-1060

[2] WerlingR. W., HwangH., YazijiH., et al.. Immunohistochemical distinction of invasive from noninvasive breast lesions. Am J Surg Pathol, 2003, 27(1): 82-90

[3] BatistatouA., StefanouD., ArkoumaniE., et al.. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo, 2003, 17(6): 573-576

[4] Reis-FilhoJ. S., SchmidttF. C.. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol, 2002, 9(5): 280-289

[5] JingH. B., DingY. Q., GaoL. X.. Role of p63 protein in differential diagnosis of breast benign and malignant lesions. J Diag Pathol (Chinese), 2004, 11(5): 21-23

[6] LiuT. Q., WangM. H., XingG. Y., et al.. Expression and significance of p63 protein in breast lesions. J Diag Pathol (Chinese), 2004, 11(4): 34-36

[7] MoritaniS., KushimaR., SugiharaH., et al.. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol, 2002, 15(4): 397-405

[8] Douglas-JonesA., ShahV., MorganJ., et al.. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology, 2005, 47(2): 202-208

[9] Lacroix-TrikiM., MeryE., VoigtJ. J., et al.. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch, 2003, 442(6): 548-554